Concord Drugs Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	10.55	3.36	4.72	9.86	15.94
Depreciation & Amortization	13.67	14.31	15.55	16.26	17.65
Other Operating Activities	16.78	21.65	17.95	15.16	13.84
Change in Accounts Receivable	-107.77	-8.75	-40.17	128.79	-21.3
Change in Inventory	-2.47	-23.46	-28.58	-6.86	-56.18
Change in Accounts Payable	-5.74	43.64	-18.35	-85.48	40.31
Change in Income Taxes	2.08	-0.18	-1.58	-3.24	2.01
Change in Other Net Operating Assets	5.25	-13.35	58.37	-57.85	-4.52
Operating Cash Flow	-67.66	37.22	7.92	16.63	7.74
Operating Cash Flow Growth	-	369.77%	-52.36%	114.81%	4778912.35%
Capital Expenditures	-11.67	-23.33	-10.18	-8.57	-24.56
Cash Acquisitions	-	-	-	-14.15	-
Investment in Securities	0.34	0.14	0.09	0.06	-
Other Investing Activities	-	0	-	-	0.12
Investing Cash Flow	-11.33	-23.18	-10.09	-22.66	-24.44
Short-Term Debt Issued	-	-	17.23	-	47.3
Long-Term Debt Issued	4.82	6.79	-	-	-
Total Debt Issued	4.82	6.79	17.23	-	47.3
Short-Term Debt Repaid	-40.75	-0.8	-	-1.56	-
Long-Term Debt Repaid	-	-	-12.66	-0.35	-12.69
Total Debt Repaid	-40.75	-0.8	-12.66	-1.9	-12.69
Net Debt Issued (Repaid)	-35.93	5.99	4.57	-1.9	34.61
Issuance of Common Stock	31.75	-	6.85	18.87	-
Other Financing Activities	84.74	-20.27	-8.58	-10.72	-17.83
Financing Cash Flow	80.56	-14.28	2.83	6.24	16.79
Net Cash Flow	1.57	-0.25	0.67	0.21	0.09
Free Cash Flow	-79.33	13.89	-2.26	8.06	-16.82
Free Cash Flow Margin	-10.07%	3.07%	-0.50%	1.55%	-2.85%
Free Cash Flow Per Share	-7.14	1.39	-0.23	0.87	-1.92
Cash Interest Paid	-	20.27	18.68	16.37	14.13
Cash Income Tax Paid	-	2.03	2.2	3.79	6.71
Levered Free Cash Flow	-98.9	5.23	45.42	-22.88	-31.95
Unlevered Free Cash Flow	-88.19	17.22	56.77	-12.67	-22.08
Change in Working Capital	-108.65	-2.1	-30.3	-24.64	-39.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.